{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-261706","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.369767+00:00","generated_at":"2026-05-17T00:50:59.865756+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA lifts clinical hold on Rein Therapeutics' Phase 2 trial of LTI-03 for IPF","bullets":["FDA lifted full clinical hold after Rein's Complete Response submission; agency confirmed all concerns resolved.","Company expects to resume U.S. patient enrollment in late 2025 or early 2026 across ~20 clinical sites.","Global Phase 2 RENEW trial to enroll up to 120 IPF patients; topline data expected in Q3 2026.","LTI-03 aims to slow fibrosis and promote lung repair, per CEO Brian Windsor."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-261706","json":"https://secwatch.observer/filing/0001193125-25-261706.json","markdown":"https://secwatch.observer/filing/0001193125-25-261706.md","text":"https://secwatch.observer/filing/0001193125-25-261706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525261706/0001193125-25-261706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525261706/d47241d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:50:59.865756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}